360° SearchNetwork Hot Spots Trends Time Series

Medicago Inc

Type: Company

Name: Medicago Inc

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Medicago Announces 2013 First Quarter Financial Results

/PRNewswire/ - $ Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and ... [Published Barchart - May 09 2013]

Entities: Medicago Inc, Vaccine, Influenza A H5N1 Virus, Pandemic

First reported May 08 2013 - Updated May 09 2013 - 4 reports

Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China

-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9-QUEBEC CITY, Canada I May 8, 2013 I Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly ... [Published PipelineReview - May 09 2013]

Entities: Medicago Inc, Vaccine, Pandemic, H7N9

First reported May 08 2013 - Updated May 08 2013 - 1 reports

New Vaccine Candidate for Deadly H7N9 Flu Virus

A new virus-like particle (VLP) vaccine candidate has been produced for the avian influenza A (H7N9) virus that is responsible for the current deadly flu outbreak in China.In order to produce an influenza vaccine, the manufacturer — Medicago Inc., based ... [Published PT Community - May 08 2013]

Entities: Vaccine, H7N9, Virus

First reported Apr 19 2013 - Updated Apr 20 2013 - 2 reports

Positive results for Phase I clinical trial for an H5N1 vaccine

Apr. 17, 2013 — IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical ... [Published Science Daily - Apr 20 2013]

Entities: Vaccine, Influenza A H5N1 Virus, Pandemic, Infectious Disease Research Institute

First reported Apr 17 2013 - Updated Apr 18 2013 - 7 reports

Infectious Disease Research Institute (IDRI) and Medicago, Inc. Report Positive Results for Phase I Clinical Trial for an H5N1 Vaccine

- All three configurations of adjuvant and route of administration exceeded the three CHMP criteria-SEATTLE and QUEBEC CITY, April 17, 2013 /PRNewswire-USNewswire/ --IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization ... [Published BioSpace - Apr 18 2013]

Entities: Vaccine, Infectious Disease Research Institute, Influenza A H5N1 Virus, Medicago Inc

First reported Mar 28 2013 - Updated Mar 28 2013 - 1 reports

DARPA Defense Advanced Research Projects Agency

Medicago loses $32.66-million in 2012

Medicago Inc. today released its operational and financial results for the fourth quarter and year ended Dec. 31, 2012. The company's financial statements and management report are available at www.sedar.com and at www.medicago.com."2012 was a significant ... [Published Stockwatch - Mar 28 2013]

Entities: Medicago Inc, Vaccine, Influenza A H5N1 Virus, DARPA Defense Advanced Research Projects Agency, Phase II

First reported Mar 11 2013 - Updated Mar 11 2013 - 1 reports

FDA Food & Drug Administration

DiagnoCure loses $788,237 in Q1 2013

DiagnoCure Inc. today released financial and operational results for the first quarter of 2013 ended Jan. 31, 2013. The corporation announced a net loss of $788,237 or two cents per share for this quarter. At the end of the quarter, cash, short-term investments ... [Published Stockwatch - Mar 11 2013]

Entities: DiagnoCure Inc, Gen-Probe Inc, FDA Food & Drug Administration, Colorectal Cancer, Genetics

First reported Feb 11 2013 - Updated Feb 11 2013 - 1 reports

Monday Deal Review: February 11, 2013

Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to ... [Published The Cross-Border Biotech Blog - Feb 11 2013]

Entities: Trillium, Cangene Corp, Common Shares, Toronto stock exchange, Private Placement

First reported Feb 04 2013 - Updated Feb 04 2013 - 1 reports

Monday Deal Review: February 4, 2013

Welcome to your Monday Biotech Deal Review for February 4, 2013! This week saw significant activity in the sector generally On the M&A side, Valeant continued their ongoing acquisition strategy, buying the Russian Natur Product International, a primarily ... [Published The Cross-Border Biotech Blog - Feb 04 2013]

Entities: Private Placement, Medicago Inc, Exercise Price, Natur Produkt International

First reported Jan 21 2013 - Updated Jan 21 2013 - 1 reports

Monday Deal Review: January 21, 2013

Welcome to your Monday Biotech Deal Review for January 21, 2013! Medicago made news last week with a $15 million loan agreement with an unnamed pharmaceutical company. The funds are being used for Medicago’s plant-based VLP vaccine pipeline. As the ... [Published The Cross-Border Biotech Blog - Jan 21 2013]

Entities: Medicago Inc, Toronto stock exchange, Paladin Labs Inc, YM Biosciences Inc

First reported Dec 24 2012 - Updated Dec 24 2012 - 1 reports

Monday Deal Review: December 24, 2012

Welcome to your Monday Biotech Deal Review for December 24, 2012. While the past week was relatively slow as everyone prepared for holiday breaks, there was nonetheless a series of option grants, commercial agreements and even the closing of a major ... [Published The Cross-Border Biotech Blog - Dec 24 2012]

Entities: Brock University, Debenture, Medicago Inc, Stock Option

First reported Dec 17 2012 - Updated Dec 17 2012 - 1 reports

Monday Deal Review: December 17, 2012

Welcome to your Monday Biotech Deal Review for December 17, 2012. This week saw the completion of a number of previously announced acquisitions, as well as the announcement of new ones. The latter group includes Gilead’s acquisition of YM Biosciences ... [Published The Cross-Border Biotech Blog - Dec 17 2012]

Entities: Toronto stock exchange, Gilead Sciences Inc, Patheon Inc, Acquisition

Quotes

"If true, these statistics indicate that influenza vaccines can save more lives than any other single licensed medicine on the planet" says Doshi...

Expert questions US public health agency advice on influenza vaccines [Published Brightsurf Science News - May 18 2013]

Mr. Sheldon continued, "Following the recent announcement of our best in class H5N1 clinical data with IDRI, we expect to commence a pandemic readiness Phase II clinical trial, as well as a U S phase II clinical trial for our quadrivalent seasonal flu vaccine."

Medicago Announces 2013 First Quarter Financial Results [Published Barchart - May 09 2013]

...pandemic strain demonstrating our ability to be a first responder in a pandemic scenario," said Andy Sheldon , President and CEO of Medicago. "Current influenza egg based vaccine manufacturers can take upup to six months to produce a vaccine for any new strain, we have proven once again that we can cut this development time drastically.This combined with our vaccine production capacity at our pilot facility in Canada and our commercial facility in North Carolina and our best-in-class efficacy results for our H5N1 vaccine, strongly positions Medicago as a key player in addressing a potential pandemic."

Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influe ... [Published PipelineReview - May 09 2013]

...Brian Ward, Professor of Medicine & Microbiology, McGill University, member of Medicago's scientific advisory committee and Medical Officer. "This H5N1 vaccine candidate represents the next generation of flu vaccines, combining our adjuvant technology with Medicago's rapid VLP technology and the intradermal delivery device from NanoPass."

Positive results for Phase I clinical trial for an H5N1 vaccine [Published Science Daily - Apr 20 2013]

More Content

sort by: Date \| Relevance
Medicago Inc. (MDG) - Pharmaceuticals & Healthc... [Published TransWorldNews - May 21 2013]
Expert questions US public health agency advice... [Published Brightsurf Science News - May 18 2013]
Medicago Announces 2013 First Quarter Financial... [Published Barchart - May 09 2013]
Medicago Announces 2013 First Quarter Financial... [Published PR Newswire: Financial Services - May 09 2013]
Medicago successfully produces VLP vaccine cand... [Published PipelineReview - May 09 2013]
New Vaccine Candidate for Deadly H7N9 Flu Virus [Published PT Community - May 08 2013]
Medicago Produces VLP Vaccine Candidate for H7N... [Published Nasdaq - May 08 2013]
New VLP vaccine candidate produced for H7N9 virus [Published News-Medical.Net - May 08 2013]
Medicago creates vaccine candidate for China's ... [Published Stockwatch - May 08 2013]
Medicago successfully produces VLP vaccine cand... [Published PR Newswire - May 08 2013]
Monday Deal Review: April 29, 2013 [Published The Cross-Border Biotech Blog - Apr 29 2013]
DiagnoCure Urges Shareholders to Vote Today to ... [Published Equities.com - Apr 22 2013]
Positive results for Phase I clinical trial for... [Published Science Daily - Apr 20 2013]
Phase I Trial Demonstrates Positive Results for... [Published MedIndia - Apr 19 2013]
Infectious Disease Research Institute (IDRI) an... [Published BioSpace - Apr 18 2013]
Phase I clinical trial for H5N1 vaccine yields ... [Published Pharmacy Choice - Apr 18 2013]
Phase I clinical trial for H5N1 vaccine yields ... [Published TruthDive - Apr 18 2013]
IDRI, Medicago announce positive Phase I clinic... [Published News-Medical.Net - Apr 18 2013]
FDA Advisory Committee Recommends Approval of B... [Published BioMedReports - Apr 18 2013]
Medicago, IDRI's vaccine trial exceeds CHMP cri... [Published Stockwatch - Apr 17 2013]
IDRI and Medicago Report Positive Results for P... [Published FinanzNachrichten.de - Apr 17 2013]
Medicago and IDRI Reports Positive Results for ... [Published ABC News 4 Charleston - Apr 17 2013]
DiagnoCure holder Axelrod proposes Dozois, Guay... [Published Stockwatch - Apr 15 2013]
Nominations pursuant to advance notice policy [Published Morningstar.com - Apr 15 2013]
IDRI and Medicago to present data at the World ... [Published PR Newswire: Health - Apr 09 2013]
Medicago and IDRI to present data at the World ... [Published PR Newswire: Health - Apr 09 2013]
Medicago loses $32.66-million in 2012 [Published Stockwatch - Mar 28 2013]
Medicago Announces 2012 Fourth Quarter and Year... [Published PR Newswire - Mar 28 2013]
DiagnoCure loses $788,237 in Q1 2013 [Published Stockwatch - Mar 11 2013]
Medicago Invited to Present at Upcoming U.S. In... [Published PR Newswire: General Business - Feb 26 2013]

Blogs

sort by: Date \| Relevance
Monday Deal Review: April 29, 2013 [Published The Cross-Border Biotech Blog - Apr 29 2013] Welcome to your Monday Biotech Deal Review for April 29, 2013! This week saw Ergoresearch and Amorfix close their previously announced private offerings. Trimel, meanwhile, has raised $40 million from their public offering of 50,000,000 common shares. ...
Monday Deal Review: February 11, 2013 [Published The Cross-Border Biotech Blog - Feb 11 2013] Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to ...
Monday Deal Review: February 4, 2013 [Published The Cross-Border Biotech Blog - Feb 04 2013] Welcome to your Monday Biotech Deal Review for February 4, 2013! This week saw significant activity in the sector generally On the M&A side, Valeant continued their ongoing acquisition strategy, buying the Russian Natur Product International, a primarily ...
Monday Deal Review: January 21, 2013 [Published The Cross-Border Biotech Blog - Jan 21 2013] Welcome to your Monday Biotech Deal Review for January 21, 2013! Medicago made news last week with a $15 million loan agreement with an unnamed pharmaceutical company. The funds are being used for Medicago’s plant-based VLP vaccine pipeline. As the ...
Monday Deal Review: December 24, 2012 [Published The Cross-Border Biotech Blog - Dec 24 2012] Welcome to your Monday Biotech Deal Review for December 24, 2012. While the past week was relatively slow as everyone prepared for holiday breaks, there was nonetheless a series of option grants, commercial agreements and even the closing of a major ...

Press Releases

sort by: Date \| Relevance
Medicago Announces 2013 First Quarter Financial... [Published PR Newswire: Financial Services - May 09 2013]
Medicago successfully produces VLP vaccine cand... [Published PR Newswire - May 08 2013]
IDRI and Medicago to present data at the World ... [Published PR Newswire: Health - Apr 09 2013]
Medicago and IDRI to present data at the World ... [Published PR Newswire: Health - Apr 09 2013]
Medicago Announces 2012 Fourth Quarter and Year... [Published PR Newswire - Mar 28 2013]